Novel Azetidine-Containing TZT-1027 Analogues as Antitumor Agents
AbstractA conformational restriction strategy was used to design and synthesize nine TZT-1027 analogues. 3-Aryl-azetidine moiety was used to replace phenylethyl group of TZT-1027 at the C-terminus. These analogues exhibited moderate to excellent antiproliferative activities, and the most potent compound 1a showed IC50 values of 2.2 nM against A549 and 2.1 nM against HCT116 cell lines, respectively. However, 1a could not achieve effective inhibition at all the dose levels in the A549 xenograft model (up to 5 mg/kg, injection, once a day), which is only 16%–35% inhibition at the end of the experiment. View Full-Text
- Supplementary File 1:
Supplementary (PDF, 125 KB)
Share & Cite This Article
Yan, Q.; Wang, Y.; Zhang, W.; Li, Y. Novel Azetidine-Containing TZT-1027 Analogues as Antitumor Agents. Mar. Drugs 2016, 14, 85.
Yan Q, Wang Y, Zhang W, Li Y. Novel Azetidine-Containing TZT-1027 Analogues as Antitumor Agents. Marine Drugs. 2016; 14(5):85.Chicago/Turabian Style
Yan, Qi; Wang, Yujie; Zhang, Wei; Li, Yingxia. 2016. "Novel Azetidine-Containing TZT-1027 Analogues as Antitumor Agents." Mar. Drugs 14, no. 5: 85.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.